TSHA (43) IMCR (31) REPL (46) VOR (37) ⌘ Pro Terminal →

Lycia Therapeutics Inc. (LYCA) — RQD Stock Rating Cockpit

$27.73 +10.70% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)

Lycia Therapeutics Inc. (LYCA) carries a Roarable Rating of C- (Hold) with 59/100 RQD Confidence. The composite score sits in the neutral Hold band (59–69), meaning current holders don’t need to panic-sell while prospective buyers can wait for a move into the 70+ Buy zone.

ROARABLE C- • HOLD / WATCH Cap $1.44B

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

RQD QUANT TACHOMETERHOLD / WATCH • C-

JEV AI Jury Split (Battleground)

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D+ · Rk C

Each axis scored 0–20

12M PRICE TARGET CONE+0.4% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for LYCA)Realized 20D OHLCV Swing Band: ±4.2%

RSI-14 MOMENTUMOVERBOUGHT (>70)

82.230 Oversold · 70 Hot

ALTMAN-Z SHIELDFORTRESS SAFE (>3.0)

3.80>3.0 Fortress Safe

PIOTROSKI F-SCOREHIGH QUALITY (7–9)

7 / 99-Pt Accounting

52-WEEK LASER RANGE68% OF RANGE

L: $24$27.73H: $30

1. Money & Cash Health● MIXED

Are profits real cash in the bank?

Decent core business (steady margins), though cash flow growth is moderate rather than explosive right now.

Factor Grade: C-RQD 12 / 20

2. Big Money & Insiders● TRIMMING

Are whales & executives buying or selling?

Insiders and big institutional desks have been trimming shares rather than stepping up to buy.

Factor Grade: D+RQD 21 / 40

3. Hidden Risks & Market Weather● WATCH

SEC fine-print scan & interest-rate fit

No major SEC filing blowups, though current interest rates and Fed liquidity call for normal position sizing.

Factor Grade: CRQD 26 / 40

MULTI-MODEL JEV QUANT JURY DELIBERATION

JEV AI Jury Split (Battleground) on LYCA

Cash & Moat Bull AI

ROIC & Free Cash Flow Model

NEUTRAL (60)

14.0% ROIC with 42.0% gross margin and 2.80% FCF yield.

SEC Forensic Auditor AI

10-K Accruals & Altman-Z Guard

NEUTRAL (65)

Altman-Z 4.20 and Piotroski 7/9 pass balance-sheet audit.

Whale & Macro Hawk AI

Options Skew, 13F & Fed NetLiq

NEUTRAL (57)

21/40 institutional & smart-money positioning score with 13/20 macro alignment.

Bull Case: Why Buyers Like LYCA

✓Established market leader in Health Care with deep daily trading liquidity.

Bear Case: What Could Go Wrong

!Company executives have done more routine share selling than personal cash buying lately.

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Quantitative Research Desk

Scheduled RQD Strong Buys & Whale Accumulation Briefing (LYCA Tape Review)

✓Breakdown of the highest-scoring RQD Green-Light breakouts across our 5,200+ rated universe
✓Forensic Red-Light accounting & dilution traps to review on your watchlist
✓Includes downloadable .ics calendar invite & nightly RQD rating-change email alerts

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

LYCA // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +0.36%▲ ASCENDING CHANNEL

2026-11-01O $28.17H $28.51L $28.03C $27.73VOL 18.50M

RES: $29.21SUP: $27.32SMA50: $25.36SMA200: $26.63

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

LYCA Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 LYCA Butterfly Map → + Track LYCA →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on LYCA today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for LYCA. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for LYCA today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (LYCA)

Health Care Rank #214 of 1016 ⚔️ TSHA vs LYCA Full Matrix →

1. Head-to-Head Health Care Peer Comparison (LYCA vs. TSHA, IMCR, REPL, VOR)

Industry: Biotechnology: Biological Products (No Diagnostic Substances) (156 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Lycia Therapeutics Inc. (LYCA) ranks #214 by composite RQD confidence (59/100, grade C-) and #309 by equity capitalization ($1.44B). Within this direct 5-issuer industry benchmark cohort, LYCA leads on earnings valuation at N/A trailing P/E, while TSHA leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. LYCA currently leads its immediate peer cohort in composite quantitative strength at 59/100 (C-).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
LYCA ACTIVE Lycia Therapeutics Inc.	C-	59/100	—	—	—	+10.70%	$1.44B	Benchmark Subject
TSHA Taysha Gene Therapies Inc.	D-	43/100	—	—	-35.0%	-0.24%	$1.38B	/tsha-vs-lyca →
IMCR Immunocore Holdings plc	E	31/100	—	96.0%	-35.0%	-4.11%	$1.61B	/imcr-vs-lyca →
REPL Replimune Group Inc.	D	46/100	—	—	-35.0%	+8.28%	$1.65B	/repl-vs-lyca →
VOR Vor Biopharma Inc.	D-	37/100	—	—	-35.0%	+1.26%	$1.24B	/vor-vs-lyca →

2. LYCA Fundamental Profitability, Capital Efficiency & Balance-Sheet Forensics

TRAILING 12M & FORWARD QUANTITATIVE SNAPSHOT

Lycia Therapeutics Inc. (LYCA) operates in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care) with an equity capitalization of $1.44B, trailing P/E of N/A, forward P/E of N/A, and EV/EBITDA of N/A. Operating profitability registers a gross margin of —, operating margin of —, net profit margin of —, ROIC of —, and free cash flow yield of —, alongside an Altman Z-Score of N/A and Piotroski F-Score of N/A.

3. LYCA Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is LYCA stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Lycia Therapeutics Inc. (NASDAQ: LYCA) is rated C- (Hold / HOLD) by Roarable's 5-pillar RQD engine with a composite confidence score of 59/100 at a spot price of $27.73 (+10.70% 1D, market cap $1.44B). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 12/20, Executive Insider Alignment 13/20, FRED Macro Regime Fit 13/20, and SEC Balance-Sheet Forensics 9/20. Across 1016 tracked Health Care issuers, LYCA ranks #214 in composite RQD confidence.

How does LYCA compare to TSHA and IMCR in the Health Care sector?

Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), LYCA carries a Roarable C- (59/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, TSHA (Taysha Gene Therapies Inc.) holds a D- grade (43/100 RQD, P/E N/A, ROIC -35.0%, cap $1.38B) and IMCR (Immunocore Holdings plc) posts a E grade (31/100 RQD, P/E N/A, ROIC -35.0%, cap $1.61B). Among the 5-stock peer group, LYCA leads on earnings multiple (N/A) while TSHA leads on capital efficiency (-35.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for LYCA?

For Lycia Therapeutics Inc. (LYCA), key quantitative strengths include Established market leader in Health Care with deep daily trading liquidity. and sector rank #214 in Health Care, while primary risk factors center on Company executives have done more routine share selling than personal cash buying lately. and implied 5-year growth hurdle of 8.0%/yr. Institutional options positioning shows a 50% call / 50% put premium split.

Where is LYCA trading relative to its 50-day, 200-day, and 52-week technical levels?

LYCA last traded at $27.73 (+10.70% on volume of 173,176 shares), positioning the stock +9.35% above its 50-day simple moving average ($25.36) and +4.13% above its 200-day simple moving average ($26.63). Across its 52-week range of $23.58 to $29.68, LYCA sits at the 68.0% percentile with a 14-day RSI of 82.2 (OVERBOUGHT (>70)) and an implied next-earnings move of ±4.2% ($26.57 to $28.89).

LYCA Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Should I buy, hold, or sell LYCA stock right now?

Lycia Therapeutics Inc. (LYCA) currently earns a Roarable Rating of C- (Hold — HOLD) with 59/100 RQD Confidence. Solid steady margins (steady margins), mixed timing at current multiples—hold if owned, no rush to chase.

What is LYCA's 12-month price target and RQD AI Jury consensus?

LYCA's 12-month base price target is $27.85 (range $21.72 to $32.86), backed by transparent SEC XBRL cash-flow, Form 4 insider, and CBOE options flow analysis.

Direct Sub-Reports: LYCA RQD Cockpit LYCA 12M Forecast LYCA Earnings & Move LYCA Dividends & DRIP LYCA Insiders & 13F LYCA Whale Options LYCA Profit Sankey LYCA News & Why